<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9029">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989389</url>
  </required_header>
  <id_info>
    <org_study_id>16610</org_study_id>
    <secondary_id>I9F-MC-SCAA</secondary_id>
    <nct_id>NCT02989389</nct_id>
  </id_info>
  <brief_title>A Study of LY3323795 in Healthy Participants</brief_title>
  <official_title>Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the safety of LY3323795 and the effects it
      has on the body. The study drug or placebo (sugar pill) will be given by mouth to healthy
      participants. The study has three parts. Each participant may only enroll in one part. The
      study will last 14 to 43 days, depending on the part. Screening must be completed prior to
      study start.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">September 11, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (up to Day 43)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3323795 in Plasma</measure>
    <time_frame>Predose through 144 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3323795 in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Predose through 36 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3323795 in Plasma</measure>
    <time_frame>Predose through 144 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3323795 in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Predose through 36 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change from Baseline in Plasma Amyloid Beta (Aβ)₁₋₄₀ and Aβ₁₋₄₂</measure>
    <time_frame>Predose through 144 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change from Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)₁₋₄₀ and Aβ₁₋₄₂</measure>
    <time_frame>Predose through 36 hours after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3323795 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of LY3323795 given orally in up to 2 of 3 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching LY3323795 given orally once in 1 of 3 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3323795 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of LY3323795 given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching LY3323795 given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3323795 (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3323795 given orally in Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3323795 + Itraconazole (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itraconazole given orally alone for up to 11 days in Period 2 and in combination with LY3323795 on one day in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3323795</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3323795 (Part A)</arm_group_label>
    <arm_group_label>LY3323795 (Part B)</arm_group_label>
    <arm_group_label>LY3323795 (Part C)</arm_group_label>
    <arm_group_label>LY3323795 + Itraconazole (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3323795 + Itraconazole (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females of non-childbearing potential at time of screening

          -  Have a body mass index (BMI) between 18.0 kilograms per square meter (kg/m²) and 32.0
             kg/m², inclusive

        Exclusion Criteria:

          -  Have participated, within the last 30 days, in a clinical trial involving an
             investigational product.

          -  Have a QT corrected for heart rate (QTc) (using Bazett's formula) interval value of
             greater than 450 millisecond (msec) (males) or greater than 470 msec (females)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>818-254-1624</phone>
    </contact>
    <investigator>
      <last_name>Hakop Gevorkyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>December 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
